umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Tumor radioimmunolocalization in nude mice by mono- and divalent- single-chain Fv antiplacental alkaline phosphatase antibodies.
Umeå universitet, Medicinsk fakultet, Klinisk mikrobiologi, Immunologi/immunkemi.
Umeå universitet, Medicinsk fakultet, Klinisk mikrobiologi, Immunologi/immunkemi.
Umeå universitet, Medicinsk fakultet, Strålningsvetenskaper, Diagnostisk radiologi.
Umeå universitet, Medicinsk fakultet, Strålningsvetenskaper, Radiofysik.
Visa övriga samt affilieringar
2007 (Engelska)Ingår i: Cancer Biotherapy and Radiopharmaceuticals, ISSN 1084-9785, E-ISSN 1557-8852, Vol. 22, nr 1, s. 64-72Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

One single-chain Fv antibody fragment (scFv) and a new recombinant covalently linked dimeric scFv antibody (sc(Fv)(2)) against placental alkaline phosphatase (PLAP) were investigated for selective tumor targeting. The biological behavior of these new antibodies was compared to that of the original native antibody, H7 MAb. The sc(Fv)(2)) antibody displayed convincing tumor localization properties with a rapid excretion pattern comparable to the scFv, but with a longer retention time in the tumor, and higher tumor-to-nontumor ratio (27:1), compared to the scFv (15:1), at 48 hours. For the sc(Fv)(2) antibody, more than 50% of the remaining activity in the mouse was present in the tumor between 24 and 48 hours after the injection. With this antibody, scintigraphic visualization of the tumor was also possible 1 week after the injection. It is concluded that this sc(Fv)(2) antibody fragment, with two binding sites, displays properties suitable for in vivo targeting of PLAP expressing tumors.

Ort, förlag, år, upplaga, sidor
2007. Vol. 22, nr 1, s. 64-72
Identifikatorer
URN: urn:nbn:se:umu:diva-21194DOI: 10.1089/cbr.2007.340PubMedID: 17627415OAI: oai:DiVA.org:umu-21194DiVA, id: diva2:210950
Tillgänglig från: 2009-04-07 Skapad: 2009-04-07 Senast uppdaterad: 2018-06-09
Ingår i avhandling
1. Recombinant antibodies and tumor targeting
Öppna denna publikation i ny flik eller fönster >>Recombinant antibodies and tumor targeting
2006 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Different antibody derived constructs are rapidly advancing as putative tools for treatment of malignant diseases. Antibody engineering has added significant new technologies to modify size, affinities, solubility, stability and biodistribution properties for immunoconjugates.

In the present thesis, the aim was to increase our knowledge on how new recombinant antibodies could be tailored to optimize localization to experimental tumors in mice.

One hybridoma, producing the monoclonal antibody H7, against placental alkaline phosphatase was used to provide CDR-containing regions for new recombinant constructs. Both single-chain variable fragments (scFv) antibodies or divalent tandem monospecific scFv [sc(Fv)2] antibodies with properties suitable for targeting were produced. By site directed mutagenesis four selective sequence substitutions were made in the VL fragment and one in the VH fragment of the antibody to improve solubility. To increase the stability of the antibody an extra -S-S- bond was introduced between the VL fragment and the VH region to create single-chain disulphide stabilized variable fragments (scdsFv) antibodies. Altogether four different recombinant scFv/scdsFv antibody constructs were produced and compared in terms of solubility, stability, affinity and production properties. The overall affinity could be maintained at the same order of magnitude as the wild type antibody (KA >109 (M-1) as determined by Biacore measurements. The antibodies could easily be expressed in the E.Coli strain BL21 Origami B (DE3). The purified recombinant antibodies could be maintained stable in concentrations up to 0.8 mg/ml.

Similarly a bivalent recombinant scFv antibody was generated from the same basic scFv, in form of a divalent tandem single-chain antibody [sc(Fv)2] by introduction of a short linker sequence between the two scFvs. The recombinant antibody was characterized by SDS-PAGE, ELISA, Western blot and Biacore analyses and was found to retain a similar high affinity as the original H7 antibody. All recombinant antibody derivates were subsequently investigated for targeting ability in vivo. Nude mice, inoculated with HeLa Hep2 tumor cells were exposed in vivo to the 125I-labelled recombinant constructs. All recombinant antibodies were found to localize and display characteristic differences in retention time within the tumor, tumor to non-tumor ratios and biodistribution properties. The tandem antibody, with a molecular weight around 60 kDa, was found to be superior compared to the scFv/scdsFv and intact antibodies in terms of discriminating properties at localization.

The immunotherapeutic potential of the intact antibodies was tested both alone with radiolabeled antibody (radioimmunotherapy, RIT) and in combination with external radiotherapy (RT). The combined effects of RT and RIT were found to cause significant growth retardation of the tumor with dramatic changes in morphology within the tumors and appearance of both necrosis and apoptosis. Increase in amount of connective tissue and cysts and decrease in cell density were observed. These result support the notion that antibodies have the potential of becoming significant tools in the arsenal of therapeutics for treatment of malignancies.

Förlag
s. 62
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1051
Forskningsämne
immunologi
Identifikatorer
urn:nbn:se:umu:diva-875 (URN)91-7264-165-7 (ISBN)
Disputation
2006-10-13, Astrid Fagraeussalen (A 103), 6A, NUS, Umeå, 09:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2006-09-25 Skapad: 2006-09-25 Senast uppdaterad: 2009-10-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Riklund Ahlström, KatrineJohansson, Lennart

Sök vidare i DiVA

Av författaren/redaktören
Riklund Ahlström, KatrineJohansson, Lennart
Av organisationen
Immunologi/immunkemiDiagnostisk radiologiRadiofysik
I samma tidskrift
Cancer Biotherapy and Radiopharmaceuticals

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 298 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf